Cargando…

Seroprevalence of SARS-CoV-2 on health professionals via Bayesian estimation: a Brazilian case study before and after vaccines

The increasing number of COVID-19 infections brought by the current pandemic has encouraged the scientific community to analyze the seroprevalence in populations to support health policies. In this context, accurate estimations of SARS-CoV-2 antibodies based on antibody tests metrics (e.g., specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Maior, Caio B.S., Lins, Isis D., Raupp, Leonardo S., Moura, Márcio C., Felipe, Felipe, Santana, João M.M., Fernandes, Mariana P., Araújo, Alice V., Gomes, Ana L.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181309/
https://www.ncbi.nlm.nih.gov/pubmed/35691330
http://dx.doi.org/10.1016/j.actatropica.2022.106551
_version_ 1784723738613252096
author Maior, Caio B.S.
Lins, Isis D.
Raupp, Leonardo S.
Moura, Márcio C.
Felipe, Felipe
Santana, João M.M.
Fernandes, Mariana P.
Araújo, Alice V.
Gomes, Ana L.V.
author_facet Maior, Caio B.S.
Lins, Isis D.
Raupp, Leonardo S.
Moura, Márcio C.
Felipe, Felipe
Santana, João M.M.
Fernandes, Mariana P.
Araújo, Alice V.
Gomes, Ana L.V.
author_sort Maior, Caio B.S.
collection PubMed
description The increasing number of COVID-19 infections brought by the current pandemic has encouraged the scientific community to analyze the seroprevalence in populations to support health policies. In this context, accurate estimations of SARS-CoV-2 antibodies based on antibody tests metrics (e.g., specificity and sensitivity) and the study of population characteristics are essential. Here, we propose a Bayesian analysis using IgA and IgG antibody levels through multiple scenarios regarding data availability from different information sources to estimate the seroprevalence of health professionals in a Northeastern Brazilian city: no data available, data only related to the test performance, data from other regions. The study population comprises 432 subjects with more than 620 collections analyzed via IgA/IgG ELISA tests. We conducted the study in pre- and post-vaccination campaigns started in Brazil. We discuss the importance of aggregating available data from various sources to create informative prior knowledge. Considering prior information from the USA and Europe, the pre-vaccine seroprevalence means are 8.04% and 10.09% for IgG and 7.40% and 9.11% for IgA. For the post-vaccination campaign and considering local informative prior, the median is 84.83% for IgG, which confirms a sharp increase in the seroprevalence after vaccination. Additionally, stratification considering differences in sex, age (younger than 30 years, between 30 and 49 years, and older than 49 years), and presence of comorbidities are provided for all scenarios.
format Online
Article
Text
id pubmed-9181309
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-91813092022-06-10 Seroprevalence of SARS-CoV-2 on health professionals via Bayesian estimation: a Brazilian case study before and after vaccines Maior, Caio B.S. Lins, Isis D. Raupp, Leonardo S. Moura, Márcio C. Felipe, Felipe Santana, João M.M. Fernandes, Mariana P. Araújo, Alice V. Gomes, Ana L.V. Acta Trop Article The increasing number of COVID-19 infections brought by the current pandemic has encouraged the scientific community to analyze the seroprevalence in populations to support health policies. In this context, accurate estimations of SARS-CoV-2 antibodies based on antibody tests metrics (e.g., specificity and sensitivity) and the study of population characteristics are essential. Here, we propose a Bayesian analysis using IgA and IgG antibody levels through multiple scenarios regarding data availability from different information sources to estimate the seroprevalence of health professionals in a Northeastern Brazilian city: no data available, data only related to the test performance, data from other regions. The study population comprises 432 subjects with more than 620 collections analyzed via IgA/IgG ELISA tests. We conducted the study in pre- and post-vaccination campaigns started in Brazil. We discuss the importance of aggregating available data from various sources to create informative prior knowledge. Considering prior information from the USA and Europe, the pre-vaccine seroprevalence means are 8.04% and 10.09% for IgG and 7.40% and 9.11% for IgA. For the post-vaccination campaign and considering local informative prior, the median is 84.83% for IgG, which confirms a sharp increase in the seroprevalence after vaccination. Additionally, stratification considering differences in sex, age (younger than 30 years, between 30 and 49 years, and older than 49 years), and presence of comorbidities are provided for all scenarios. Elsevier B.V. 2022-09 2022-06-09 /pmc/articles/PMC9181309/ /pubmed/35691330 http://dx.doi.org/10.1016/j.actatropica.2022.106551 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Maior, Caio B.S.
Lins, Isis D.
Raupp, Leonardo S.
Moura, Márcio C.
Felipe, Felipe
Santana, João M.M.
Fernandes, Mariana P.
Araújo, Alice V.
Gomes, Ana L.V.
Seroprevalence of SARS-CoV-2 on health professionals via Bayesian estimation: a Brazilian case study before and after vaccines
title Seroprevalence of SARS-CoV-2 on health professionals via Bayesian estimation: a Brazilian case study before and after vaccines
title_full Seroprevalence of SARS-CoV-2 on health professionals via Bayesian estimation: a Brazilian case study before and after vaccines
title_fullStr Seroprevalence of SARS-CoV-2 on health professionals via Bayesian estimation: a Brazilian case study before and after vaccines
title_full_unstemmed Seroprevalence of SARS-CoV-2 on health professionals via Bayesian estimation: a Brazilian case study before and after vaccines
title_short Seroprevalence of SARS-CoV-2 on health professionals via Bayesian estimation: a Brazilian case study before and after vaccines
title_sort seroprevalence of sars-cov-2 on health professionals via bayesian estimation: a brazilian case study before and after vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181309/
https://www.ncbi.nlm.nih.gov/pubmed/35691330
http://dx.doi.org/10.1016/j.actatropica.2022.106551
work_keys_str_mv AT maiorcaiobs seroprevalenceofsarscov2onhealthprofessionalsviabayesianestimationabraziliancasestudybeforeandaftervaccines
AT linsisisd seroprevalenceofsarscov2onhealthprofessionalsviabayesianestimationabraziliancasestudybeforeandaftervaccines
AT rauppleonardos seroprevalenceofsarscov2onhealthprofessionalsviabayesianestimationabraziliancasestudybeforeandaftervaccines
AT mouramarcioc seroprevalenceofsarscov2onhealthprofessionalsviabayesianestimationabraziliancasestudybeforeandaftervaccines
AT felipefelipe seroprevalenceofsarscov2onhealthprofessionalsviabayesianestimationabraziliancasestudybeforeandaftervaccines
AT santanajoaomm seroprevalenceofsarscov2onhealthprofessionalsviabayesianestimationabraziliancasestudybeforeandaftervaccines
AT fernandesmarianap seroprevalenceofsarscov2onhealthprofessionalsviabayesianestimationabraziliancasestudybeforeandaftervaccines
AT araujoalicev seroprevalenceofsarscov2onhealthprofessionalsviabayesianestimationabraziliancasestudybeforeandaftervaccines
AT gomesanalv seroprevalenceofsarscov2onhealthprofessionalsviabayesianestimationabraziliancasestudybeforeandaftervaccines